Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
Opevesostat is an investigational new drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a non-steroidal, selective inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme) discovered by Orion Corporation and currently undergoing clinical development by Merck &amp; Co., Inc. Opevesostat's mechanism of action involves suppressing the production of steroid hormones and their precursors that may activate the androgen receptor signaling pathway, which is crucial in prostate cancer progression. As of 2024, opevesostat is being evaluated in two Phase 3 clinical trials, OMAHA1 and OMAHA2a, which are assessing its efficacy and safety in combination with hormone replacement therapy for patients with mCRPC who have failed prior treatments.
References.
 ;templatestyles src="Reflist/styles.css" / ;